Ultimovacs ASA
OSE:ULTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ultimovacs ASA
Cash Equivalents
Ultimovacs ASA
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
Ultimovacs ASA
OSE:ULTI
|
Cash Equivalents
kr107.4m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Cash Equivalents
kr130.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Cash Equivalents
kr187.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Cash Equivalents
$60.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Cash Equivalents
kr6.1m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-29%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Cash Equivalents
kr180.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-6%
|
|
Ultimovacs ASA
Glance View
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.
See Also
What is Ultimovacs ASA's Cash Equivalents?
Cash Equivalents
107.4m
NOK
Based on the financial report for Dec 31, 2024, Ultimovacs ASA's Cash Equivalents amounts to 107.4m NOK.
What is Ultimovacs ASA's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-23%
Over the last year, the Cash Equivalents growth was -60%. The average annual Cash Equivalents growth rates for Ultimovacs ASA have been -43% over the past three years , -23% over the past five years .
